Adverum Bio (ADVM) Stock Forecast, Price Target & Predictions
ADVM Stock Forecast
Adverum Bio stock forecast is as follows: an average price target of $15.00 (represents a 160.87% upside from ADVM’s last price of $5.75) and a rating consensus of 'Buy', based on 3 wall street analysts offering a 1-year stock forecast.
ADVM Price Target
The average price target for Adverum Bio (ADVM) is $15.00 based on 1-year price targets from 3 Wall Street analysts in the past 3 months, with a price target range of $28.00 to $2.00. This represents a potential 160.87% upside from ADVM's last price of $5.75.
ADVM Analyst Ratings
According to 3 Wall Street analysts, Adverum Bio's rating consensus is 'Buy'. The analyst rating breakdown for ADVM stock is 0 'Strong Buy' (0.00%), 2 'Buy' (66.67%), 1 'Hold' (33.33%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Adverum Bio Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Nov 05, 2024 | Luca Issi | RBC Capital | $10.00 | $7.72 | 29.53% | 73.91% |
| Oct 14, 2024 | Francois Brisebois | Oppenheimer | $28.00 | $7.81 | 258.51% | 386.96% |
| Sep 20, 2024 | Graig Suvannavejh | Mizuho Securities | $20.00 | $7.50 | 166.67% | 247.83% |
| Aug 13, 2024 | Luca Issi | RBC Capital | $12.00 | $6.64 | 80.72% | 108.70% |
| Nov 11, 2022 | - | Chardan Capital | $2.00 | $0.71 | 183.65% | -65.22% |
The latest Adverum Bio stock forecast, released on Nov 05, 2024 by Luca Issi from RBC Capital, set a price target of $10.00, which represents a 29.53% increase from the stock price at the time of the forecast ($7.72), and a 73.91% increase from ADVM last price ($5.75).
Adverum Bio Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | 1 | 3 | 4 |
| Avg Price Target | $10.00 | $19.33 | $17.50 |
| Last Closing Price | $5.75 | $5.75 | $5.75 |
| Upside/Downside | 73.91% | 236.17% | 204.35% |
In the current month, the average price target of Adverum Bio stock is $10.00, according to 1 Wall Street analyst offering twelve months forecast. The average price target represents a 73.91% increase as opposed to Adverum Bio's last price of $5.75. This month's average price target is down -48.27% compared to last quarter, and down -42.86% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Nov 05, 2024 | H.C. Wainwright | Buy | Buy | Hold |
| Oct 03, 2024 | Oppenheimer | Outperform | Outperform | Hold |
| Aug 13, 2024 | RBC Capital | Sector Perform | Sector Perform | Hold |
| Jun 25, 2024 | Oppenheimer | - | Outperform | Initialise |
| Nov 11, 2022 | RBC Capital | Sector Perform | Sector Perform | Hold |
Adverum Bio's last stock rating was published by H.C. Wainwright on Nov 05, 2024. The company gave ADVM a "Buy" rating, the same as its previous rate.
Adverum Bio Financial Forecast
Adverum Bio Revenue Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Mar 18 | Mar 17 | Mar 16 | Mar 15 | Sep 14 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | $7.50M | - | - | - | - | - | $250.00K | - | - | $216.00K | $462.00K | $265.00K | $203.00K | $204.00K |
| Avg Forecast | $420.45K | $500.00K | $594.60K | $707.11K | $131.25K | $125.00K | $106.00K | $127.50K | $92.00K | $76.67K | $76.67K | $76.67K | $108.57K | $253.33K | $265.00K | $377.50K | $320.00K | $208.80K | $376.89K | $181.31K | $213.68K | $85.68K |
| High Forecast | $420.45K | $500.00K | $594.60K | $707.11K | $131.25K | $125.00K | $106.00K | $127.75K | $92.00K | $76.67K | $76.67K | $76.67K | $108.57K | $253.33K | $265.00K | $377.50K | $320.00K | $250.56K | $452.27K | $217.58K | $256.42K | $102.82K |
| Low Forecast | $420.45K | $500.00K | $594.60K | $707.11K | $131.25K | $125.00K | $106.00K | $127.25K | $92.00K | $76.67K | $76.67K | $76.67K | $108.57K | $253.33K | $265.00K | $377.50K | $320.00K | $167.04K | $301.51K | $145.05K | $170.95K | $68.54K |
| # Analysts | 1 | 1 | 1 | 1 | 3 | 1 | 1 | 1 | 4 | 4 | 6 | 4 | 4 | 7 | 4 | 3 | 7 | 9 | 14 | 12 | 9 | 11 |
| Surprise % | - | - | - | - | - | - | - | - | 81.52% | - | - | - | - | - | 0.94% | - | - | 1.03% | 1.23% | 1.46% | 0.95% | 2.38% |
Adverum Bio's average Quarter revenue forecast for Mar 24 based on 1 analysts is $127.50K, with a low forecast of $127.25K, and a high forecast of $127.75K. ADVM's average Quarter revenue forecast represents a -98.30% decrease compared to the company's last Quarter revenue of $7.50M (Mar 21).
Adverum Bio EBITDA Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Mar 18 | Mar 17 | Mar 16 | Mar 15 | Sep 14 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 3 | 1 | 1 | 1 | 4 | 4 | 6 | 4 | 4 | 7 | 4 | 3 | 7 | 9 | 14 | 12 | 9 | 11 |
| EBITDA | - | - | - | - | - | - | - | - | $-27.27M | $-36.55M | $-26.58M | $-27.90M | $-22.31M | $-20.19M | $-15.20M | $-13.99M | $-13.52M | $-16.74M | $-15.58M | $-15.07M | $-9.39M | $-8.21M |
| Avg Forecast | $-84.09K | $-100.00K | $-118.92K | $-141.42K | $-26.25K | $-25.00K | $-21.20K | $-25.50K | $-33.73M | $-15.33K | $-15.33K | $-15.33K | $-19.76M | $-50.67K | $-53.00K | $-75.50K | $-16.93M | $-16.16M | $-12.06M | $-8.93M | $-9.86M | $-3.44M |
| High Forecast | $-84.09K | $-100.00K | $-118.92K | $-141.42K | $-26.25K | $-25.00K | $-21.20K | $-25.45K | $-26.98M | $-15.33K | $-15.33K | $-15.33K | $-15.80M | $-50.67K | $-53.00K | $-75.50K | $-13.54M | $-12.93M | $-9.65M | $-7.14M | $-7.89M | $-2.75M |
| Low Forecast | $-84.09K | $-100.00K | $-118.92K | $-141.42K | $-26.25K | $-25.00K | $-21.20K | $-25.55K | $-40.47M | $-15.33K | $-15.33K | $-15.33K | $-23.71M | $-50.67K | $-53.00K | $-75.50K | $-20.31M | $-19.40M | $-14.48M | $-10.71M | $-11.83M | $-4.13M |
| Surprise % | - | - | - | - | - | - | - | - | 0.81% | 2384.07% | 1733.78% | 1819.80% | 1.13% | 398.51% | 286.85% | 185.37% | 0.80% | 1.04% | 1.29% | 1.69% | 0.95% | 2.39% |
undefined analysts predict ADVM's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than Adverum Bio's previous annual EBITDA (undefined) of $NaN.
Adverum Bio Net Income Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Mar 18 | Mar 17 | Mar 16 | Mar 15 | Sep 14 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 3 | 1 | 1 | 1 | 4 | 4 | 6 | 4 | 4 | 7 | 4 | 3 | 7 | 9 | 14 | 12 | 9 | 11 |
| Net Income | - | - | - | - | - | - | - | - | $-28.44M | $-37.63M | $-27.77M | $-29.20M | $-22.91M | $-18.93M | $-16.12M | $-14.95M | $-14.49M | $-17.20M | $-16.10M | $-15.39M | $-9.51M | $-8.26M |
| Avg Forecast | $-25.68M | $-27.54M | $-29.37M | $-28.23M | $-28.36M | $-27.29M | $-30.64M | $-29.32M | $-35.17M | $-67.39M | $-71.59M | $-60.24M | $-19.51M | $-61.17M | $-55.26M | $-61.30M | $-16.64M | $-16.61M | $-12.46M | $-9.12M | $-9.98M | $-3.46M |
| High Forecast | $-25.68M | $-27.54M | $-29.37M | $-24.44M | $-22.73M | $-27.29M | $-30.64M | $-29.32M | $-28.14M | $-67.39M | $-71.59M | $-60.24M | $-15.61M | $-61.17M | $-55.26M | $-61.30M | $-13.31M | $-13.29M | $-9.97M | $-7.29M | $-7.99M | $-2.77M |
| Low Forecast | $-25.68M | $-27.54M | $-29.37M | $-31.81M | $-30.96M | $-27.29M | $-30.64M | $-29.32M | $-42.21M | $-67.39M | $-71.59M | $-60.24M | $-23.42M | $-61.17M | $-55.26M | $-61.30M | $-19.96M | $-19.93M | $-14.96M | $-10.94M | $-11.98M | $-4.15M |
| Surprise % | - | - | - | - | - | - | - | - | 0.81% | 0.56% | 0.39% | 0.48% | 1.17% | 0.31% | 0.29% | 0.24% | 0.87% | 1.04% | 1.29% | 1.69% | 0.95% | 2.39% |
Adverum Bio's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. ADVM's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).
Adverum Bio SG&A Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Mar 18 | Mar 17 | Mar 16 | Mar 15 | Sep 14 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 3 | 1 | 1 | 1 | 4 | 4 | 6 | 4 | 4 | 7 | 4 | 3 | 7 | 9 | 14 | 12 | 9 | 11 |
| SG&A | - | - | - | - | - | - | - | - | $16.16M | $13.65M | $11.35M | $10.60M | $9.04M | $8.28M | $7.39M | $7.13M | $5.58M | $5.37M | $7.99M | $8.32M | $4.14M | $2.40M |
| Avg Forecast | $11.60M | $13.80M | $16.41M | $19.51M | $3.62M | $3.45M | $2.92M | $3.52M | $2.51M | $2.09M | $2.09M | $2.09M | $2.96M | $6.91M | $7.23M | $10.30M | $8.73M | $5.70M | $10.28M | $4.95M | $5.83M | $2.34M |
| High Forecast | $11.60M | $13.80M | $16.41M | $19.51M | $3.62M | $3.45M | $2.92M | $3.52M | $2.51M | $2.09M | $2.09M | $2.09M | $2.96M | $6.91M | $7.23M | $10.30M | $8.73M | $6.83M | $12.34M | $5.94M | $6.99M | $2.80M |
| Low Forecast | $11.60M | $13.80M | $16.41M | $19.51M | $3.62M | $3.45M | $2.92M | $3.51M | $2.51M | $2.09M | $2.09M | $2.09M | $2.96M | $6.91M | $7.23M | $10.30M | $8.73M | $4.56M | $8.22M | $3.96M | $4.66M | $1.87M |
| Surprise % | - | - | - | - | - | - | - | - | 6.44% | 6.53% | 5.43% | 5.07% | 3.05% | 1.20% | 1.02% | 0.69% | 0.64% | 0.94% | 0.78% | 1.68% | 0.71% | 1.03% |
Adverum Bio's average Quarter SG&A projection for Mar 24 is $3.52M, based on 1 Wall Street analysts, with a range of $3.51M to $3.52M. The forecast indicates a -78.23% fall compared to ADVM last annual SG&A of $16.16M (Mar 21).
Adverum Bio EPS Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Mar 18 | Mar 17 | Mar 16 | Mar 15 | Sep 14 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 3 | 1 | 1 | 1 | 4 | 4 | 6 | 4 | 4 | 7 | 4 | 3 | 7 | 9 | 14 | 12 | 9 | 11 |
| EPS | - | - | - | - | - | - | - | - | $-0.29 | $-0.38 | $-0.31 | $-0.36 | $-0.31 | $-0.26 | $-0.25 | $-0.23 | $-0.23 | $-0.30 | $-0.38 | $-0.57 | $-0.38 | $-0.37 |
| Avg Forecast | $-1.23 | $-1.32 | $-1.41 | $-1.35 | $-1.36 | $-1.31 | $-1.47 | $-1.40 | $-3.81 | $-3.23 | $-3.43 | $-2.89 | $-2.73 | $-2.93 | $-2.65 | $-2.94 | $-2.68 | $-0.28 | $-0.24 | $-0.23 | $-0.42 | $-0.09 |
| High Forecast | $-1.23 | $-1.32 | $-1.41 | $-1.17 | $-1.09 | $-1.31 | $-1.47 | $-1.40 | $-3.81 | $-3.23 | $-3.43 | $-2.89 | $-2.73 | $-2.93 | $-2.65 | $-2.94 | $-2.68 | $-0.22 | $-0.19 | $-0.18 | $-0.34 | $-0.07 |
| Low Forecast | $-1.23 | $-1.32 | $-1.41 | $-1.52 | $-1.48 | $-1.31 | $-1.47 | $-1.40 | $-3.81 | $-3.23 | $-3.43 | $-2.89 | $-2.73 | $-2.93 | $-2.65 | $-2.94 | $-2.68 | $-0.34 | $-0.29 | $-0.28 | $-0.50 | $-0.11 |
| Surprise % | - | - | - | - | - | - | - | - | 0.08% | 0.12% | 0.09% | 0.12% | 0.11% | 0.09% | 0.09% | 0.08% | 0.09% | 1.07% | 1.58% | 2.48% | 0.90% | 4.08% |
According to undefined Wall Street analysts, Adverum Bio's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to ADVM previous annual EPS of $NaN (undefined).
Adverum Bio Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| BCEL | Atreca | $0.09 | $4.00 | 4344.44% | Buy |
| ONCT | Oncternal Therapeutics | $1.16 | $28.00 | 2313.79% | Buy |
| PASG | Passage Bio | $0.54 | $6.00 | 1011.11% | Buy |
| QURE | uniQure | $5.85 | $53.67 | 817.44% | Buy |
| ANTX | AN2 Therapeutics | $1.23 | $8.75 | 611.38% | Buy |
| KOD | Kodiak Sciences | $5.90 | $31.60 | 435.59% | Buy |
| AVTE | Aerovate Therapeutics | $2.61 | $13.00 | 398.08% | Hold |
| RCKT | Rocket Pharmaceuticals | $12.79 | $45.20 | 253.40% | Buy |
| ACRV | Acrivon Therapeutics | $6.44 | $21.83 | 238.98% | Buy |
| SLDB | Solid Biosciences | $5.23 | $17.50 | 234.61% | Buy |
| FIXX | Q32 Bio | $0.93 | $2.70 | 190.32% | Buy |
| AFMD | Affimed | $2.64 | $7.50 | 184.09% | Buy |
| RZLT | Rezolute | $4.86 | $13.50 | 177.78% | Buy |
| STOK | Stoke Therapeutics | $11.27 | $30.60 | 171.52% | Buy |
| ADVM | Adverum Bio | $5.75 | $15.00 | 160.87% | Buy |
| ABSI | Absci | $2.55 | $6.00 | 135.29% | Buy |
| KZR | Kezar Life Sciences | $7.62 | $17.50 | 129.66% | Buy |
| ADAG | Adagene | $2.26 | $5.00 | 121.24% | Buy |
| MREO | Mereo BioPharma Group | $3.68 | $6.75 | 83.42% | Buy |
| GLMD | Galmed Pharmaceuticals | $2.80 | $5.00 | 78.57% | Buy |
| MGTX | MeiraGTx | $5.92 | $9.00 | 52.03% | Buy |
| RYTM | Rhythm Pharmaceuticals | $59.03 | $55.20 | -6.49% | Buy |